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Abstract 
The clinical diagnosis of renal cell carcinoma (RCC) is radiographic. Effective imaging of 
the kidneys can be achieved by ultrasound, CT or MRI [Chawla et al.: J Urol 2006;175:425–
431]. Solid lesions detected by ultrasound and those showing enhancement on cross-
sectional imaging are considered malignant until proven otherwise. The standard of care 
for clinically localized RCC remains surgical resection due to the favorable prognosis 
associated with surgery and the relative ineffectiveness of systemic therapy. Since 
patients with localized RCC are often symptom-free, they sometimes refuse to receive 
surgical treatment or are left untreated based on a diagnosis of benign lesions. There are 
also cases where an RCC is relatively large and causes symptoms but is not treated 
surgically because of complications and other reasons. We report a 54-year-old male who 
underwent a difficult radical nephrectomy 9 years after the primary RCC malignancy 
diagnosis. 
 
Case Presentation 
The patient is a 54-year-old male who was referred to our clinic due to a large abdominal mass. He 
complained of early satiety, anorexia, weakness and weight loss during the 6 months before admission. 
Nine years ago, he had noticed the presence of a 4- to 5-cm right renal mass. His chief complaint at that 
time was intermittent gross hematuria. He was advised to have surgery but due to financial constraints, 
he refused the surgery. In the physical examination, a distended abdomen was evident in the supine  
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position (fig. 1). A right-sided grade III varicocele was apparent. BMI was 22. In the hematological 
evaluation, Hgb was 10.5 g/dl. Other biochemistry data was normal. In abdominopelvic sonograghy a 
large solid mass of 25 × 15 cm was reported. A huge hypervascularized mass was evident on MRI, which 
occupied all of the right side of the abdomen without any evidence of direct invasion of the inferior vena 
cava (fig. 2). Chest X-ray was negative for metastasis. A whole body bone scan was negative for skeletal 
metastasis. He underwent right radical nephrectomy by laparotomy incision (fig. 3). After a very 
difficult procedure with severe bleeding, the tumor (fig. 4), weighing 2,500 g and measuring 25 × 20 × 
12 cm, was excised. Its histopathology diagnosis was consistent with clear cell RCC with grade 2 
Fuhrman nuclear grading. The patient is still well one year after operation as revealed by CT scan 
(fig. 5). 
Discussion 
Due to the increased use of diagnostic imaging for evaluating patients with abdominal 
symptomatology, the incidence of RCC has increased dramatically during the last three 
decades and the size of the lesions detected is constantly decreasing [2, 3]. Incidental 
detection of asymptomatic tumors now accounts for 48–66% of all such lesions [4]. 
Median patient age at RCC diagnosis is now 66 years with the greatest increase in patients 
70–90 years old [5]. The percentage of patients presenting with metastatic disease at 
initial diagnosis remains at 25–35% [6]. Prompt surgical excision remains the standard of 
care for localized enhancing renal tumors because of the limited efficacy of systemic 
therapies for advanced disease [7, 8]. However, recent data demonstrate that despite 
earlier diagnosis and treatment there has been no significant decrease in cancer-specific 
or overall mortality, suggesting an over-treatment bias [3]. Renal masses diagnosed in 
older and comorbid patients represent a challenge with regard to treatment. In the 
published literature, only limited experience with ‘watchful waiting’ or ‘active 
surveillance’ with regard to renal masses is available. Currently, the natural history of 
untreated localized renal tumors is being defined through active surveillance series. A 
recent meta-analysis of active surveillance series revealed that the majority of renal 
tumors demonstrated slow interval growth with an average growth rate of 0.28 cm/year 
[1]. Moreover, a subset of approximately 30% of renal tumors did not demonstrate any 
difference in pathology between growing and nongrowing tumors, and no predictive 
clinical or radiographic characteristics could be identified in these tumors [9]. Potential 
predictors of future tumor growth include gender, patient age on presentation and 
radiographic tumor characteristics. A recent report by Kouba et al. [10] noted a 
significant correlation between patient age on presentation and linear tumor growth rates. 
Their data suggests that tumors detected in younger patients exhibit increased linear 
growth compared to older patients. Potential radiographic predictors of renal lesion 
growth investigated included lesion size on presentation, presence of cystic components, 
and the presence of multifocal disease on presentation. In our opinion, the most 
important question related to observational strategies in RCC management is how the 
clinical outcome for the patients is affected. As the most definite measure of outcome, we 
have focused on survival. The 100% rate of 5-year cancer-specific survival for patients 
with tumors ≤4 cm in size is similar in all of the studies. Chawla et al. [11], in their meta-
analysis of worldwide literature, reported a progression rate of only 1% in 286 tumors 
between 1.73 and 4.08 cm in size. The length of the follow-up period is essential, as 
demonstrated by Abou et al. [12] in their long-term follow-up paper. They found 
progression to metastatic disease in 2 of 35 patients (5.7%) after 29 and 40 months, 
respectively, in a group of tumors ≤4 cm in diameter. This underlines the progressive 
nature of RCC. In large tumors, size is related to a poorer prognosis, and nearly 40% of  
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the patients have metastatic disease at higher stages. A median diameter of 7.5 cm is 
related to a 40% rise of synchronous metastatic disease. It is estimated that the odds of 
synchronous metastatic disease is increased by 22–38% by each 1-cm increase in tumor 
size [13]. The perioperative mortality of some of the patients is important and should be 
discussed. The rate is difficult to determine. However, Nuttall et al. [14] report an in-
hospital mortality rate of 3.2 and 4.7% among patients between 70–79 and >80 years of 
age, respectively. Most renal masses seem to grow slowly. Most authors report the mean 
tumor growth rate to be between 0.06 and 0.21 cm/year for tumors ≤4 cm in size [4]. For 
larger tumors, a mean tumor growth rate of 0.39 cm/year is reported [15]. However, 
delayed intervention of ≥1 year after diagnosis does not seem to worsen the prognosis for 
later metastatic disease [16]. There is wide variability of observed renal lesions with regard 
to growth kinetics [17]. Kato et al. [18] described rapidly growing tumors that increased 
in diameter at 20 times the rate of slowly growing lesions. While it was suggested that 
tumors that are destined to grow and possibly metastasize do so early and most small 
tumors grow slowly or not at all [17], to our knowledge no correlation between size at 
presentation and the growth rate has been firmly established. In the Kunkle DA et al. 
series [19], only 1 patient showed metastatic disease during observation. In this 84-year-
old patient, a 2-cm mass grew to 8 cm during 54 months of follow-up. With only 3 such 
cases reported in the literature, it is difficult to accurately establish the rate at which 
sporadic, clinically localized RCC progress to metastatic disease while under surveillance. 
The patients with symptoms trended toward a more rapid growth rate than asymptomatic 
patients. However, progression of symptoms may warrant definitive therapy and should 
be carefully considered in patient discussions. Age was perhaps the strongest predictor of 
tumor growth, with younger patients having more rapid growth rates than older patients 
[7]. Fujimoto et al. [20] analyzed the doubling time in 18 cases of renal carcinoma and 
reported a doubling time of 466 ± 84.6 days for primary lesions and 89.4 ± 43 days for 
metastatic lesions in the lungs. The risk of developing metastatic disease is the primary 
indication for initiating active surveillance of enhancing renal tumors. Younger patients 
may be more susceptible to rapid growth and should be treated accordingly. 
Conclusion 
The majority of enhancing renal tumors undergoing active surveillance demonstrates 
slow interval growth. Tumor growth kinetics may provide a way of identifying aggressive 
behavior of renal tumors. For this reason, immediate surgical excision is indicated for 
patients with enhancing renal tumors who are acceptable surgical candidates. The risk of 
disease progression is significantly higher in patients with larger renal masses (>4 cm). 
The data from this case report and those of others support that even the rapidly growing 
or large renal tumors may be managed expectantly, but with increased vigilance [15]. 
Delayed intervention does not appear to adversely impact pathological outcomes. This 
case is the first report about the obligate observation of a large renal tumor for the long 
period of 9 years without finding any evidence of metastasis. 
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Fig. 1. The formal appearance of the abdomen before operation. Tumoral distention of the abdomen is 
evident. 
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Fig. 2. MRI of the abdomen, multiple views. The large tumor occupied half of the abdomen. 
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Fig. 3. The appearance of the tumor after peritoneal opening. 
 
 
 
Fig. 4. The hypervascularized tumor after excision. 
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Fig. 5. Postoperative CT scan, one year after operation, revealing unremarkable, tumor-free state. 
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